Provided by Tiger Trade Technology Pte. Ltd.

Nexalin Technology, Inc.

0.3101
-0.0053-1.68%
Volume:88.44K
Turnover:27.42K
Market Cap:6.83M
PE:-0.67
High:0.3199
Open:0.3132
Low:0.3021
Close:0.3154
52wk High:2.00
52wk Low:0.3021
Shares:22.01M
Float Shares:19.29M
Volume Ratio:1.10
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4623
EPS(LYR):-0.5016
ROE:-240.25%
ROA:-119.22%
PB:4.49
PE(LYR):-0.62

Loading ...

Nuix (ASX:NXL) Shares Ask Whether Neo Growth Justifies Premium P/E

Simply Wall St.
·
Yesterday

Nexalin Technology Enters USD 1.17 Million Unsecured Note Financing with Institutional Investor

Reuters
·
Aug 22

Nexalin Technology Prices Registered Direct Offering of 2,419,355 Shares at $0.31 Each

Reuters
·
Aug 21

Nexalin Falls Below NASDAQ Stockholders’ Equity Minimum, Faces Delisting Risk

Reuters
·
Aug 17

Nexalin Q2 FY26 Net Loss Widens 42% to $2.24 Million; Revenue Drops 83% to $12,161

Reuters
·
Aug 13

Nexalin Technology Menggelar Rapat Tahunan Pemegang Saham; Kuorum Tercapai 63,2%

Reuters
·
Aug 12

Nexalin Technology Inc Expected to Post a Loss of 10 Cents a Share - Earnings Preview

Reuters
·
Jul 31

RBC Capital Keeps Their Buy Rating on Nuix Ltd. (NXL)

TIPRANKS
·
Jul 29

Nexalin Appeals NASDAQ Delisting Notice After Failing $1 Minimum Bid Requirement

Reuters
·
Jul 28

Nexalin Technology Announces Annual Shareholder Meeting

Reuters
·
Jun 30

Nexalin Technology investigator wins award for neurostimulation research

TIPRANKS
·
Jun 23

Nexalin Technology lowers shareholder meeting quorum requirement to one-third in bylaw overhaul

Reuters
·
Jun 18

Nexalin says open-label pilot trial data show 77.8% anxiety response with DIFS brain-stimulation device

Reuters
·
Jun 16

Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial

MT Newswires Live
·
Jun 10

Nexalin Technology completes neurostimulation protocol trial

TIPRANKS
·
Jun 10

Nexalin reports 77.8% anxiety response rate in Brazil trial of DIFS neurostimulation device

Reuters
·
Jun 10

Nexalin Technology - No Serious Adverse Events or Seizures Reported in Nexalin Trial

THOMSON REUTERS
·
Jun 10

Nexalin Technology - Reports 77.8% Anxiety Response Rate at End of Treatment

THOMSON REUTERS
·
Jun 10

Nexalin Technology - Overall Quality of Life Improves Significantly at End of Treatment

THOMSON REUTERS
·
Jun 10

Nexalin Technology - Completes 8-Week Clinical Trial of 15 Ma, 77.5 Hz Neurostimulation in Anxiety

THOMSON REUTERS
·
Jun 10